Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics


Karyopharm Therapeutics Inc. (KPTI): $4.94

0.03 (+0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

KPTI POWR Grades

  • KPTI scores best on the Value dimension, with a Value rank ahead of 86.38% of US stocks.
  • KPTI's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • KPTI's current lowest rank is in the Stability metric (where it is better than 1.61% of US stocks).

KPTI Stock Summary

  • KARYOPHARM THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.35% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.59 for KARYOPHARM THERAPEUTICS INC; that's greater than it is for just 4.08% of US stocks.
  • As for revenue growth, note that KPTI's revenue has grown 110.5% over the past 12 months; that beats the revenue growth of 92.48% of US companies in our set.
  • Stocks that are quantitatively similar to KPTI, based on their financial statements, market capitalization, and price volatility, are EYEN, ABSI, GNTX, SENS, and VYNE.
  • KPTI's SEC filings can be seen here. And to visit KARYOPHARM THERAPEUTICS INC's official web site, go to www.karyopharm.com.

KPTI Valuation Summary

  • KPTI's price/earnings ratio is -3.6; this is 116.11% lower than that of the median Healthcare stock.
  • Over the past 109 months, KPTI's price/sales ratio has gone down 1021.4.

Below are key valuation metrics over time for KPTI.

Stock Date P/S P/B P/E EV/EBIT
KPTI 2022-11-01 1.5 -3.2 -3.6 -6.3
KPTI 2022-10-31 1.5 -3.3 -3.7 -6.4
KPTI 2022-10-28 1.6 -3.5 -3.9 -6.7
KPTI 2022-10-27 1.6 -3.4 -3.8 -6.5
KPTI 2022-10-26 1.6 -3.4 -3.8 -6.6
KPTI 2022-10-25 1.6 -3.4 -3.8 -6.6

KPTI Growth Metrics

    The year over year net income to common stockholders growth rate now stands at 46.17%.
  • Its 5 year revenue growth rate is now at 38131.17%.
  • Its 5 year net income to common stockholders growth rate is now at -70.07%.
Over the past 15 months, KPTI's revenue has gone up $138,100,000.

The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 251.307 -92.821 -103.553
2022-03-31 234.229 -113.425 -108.073
2021-12-31 209.819 -107.116 -124.088
2021-09-30 118.65 -163.225 -206.229
2021-06-30 102.294 -183.582 -207.912
2021-03-31 113.207 -168.111 -200.756

KPTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KPTI has a Quality Grade of C, ranking ahead of 58.11% of graded US stocks.
  • KPTI's asset turnover comes in at 0.338 -- ranking 138th of 681 Pharmaceutical Products stocks.
  • CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.

The table below shows KPTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.338 0.965 -0.614
2021-03-31 0.347 0.975 -0.545
2020-12-31 0.299 0.975 -0.534
2020-09-30 0.255 0.967 -0.576
2020-06-30 0.239 0.956 -0.607
2020-03-31 0.189 0.945 -0.671

KPTI Price Target

For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.22 Average Broker Recommendation 1.6 (Moderate Buy)

KPTI Stock Price Chart Interactive Chart >

Price chart for KPTI

KPTI Price/Volume Stats

Current price $4.94 52-week high $14.73
Prev. close $4.91 52-week low $4.00
Day low $4.80 Volume 403,400
Day high $4.96 Avg. volume 2,554,024
50-day MA $5.04 Dividend yield N/A
200-day MA $5.94 Market Cap 400.91M

Karyopharm Therapeutics Inc. (KPTI) Company Bio


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.


KPTI Latest News Stream


Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream


Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?

The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 8, 2022

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

Yahoo | November 8, 2022

Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript

KPTI earnings call for the period ending September 30, 2022.

Yahoo | November 4, 2022

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 19.64% and 3.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that two abstracts detailing new selinexor data have been selected for poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022. The presentations include results from the Phase 1 open-label, dose-escalation study of selinexor in combination with ruxolitinib in patients with treatment-

Yahoo | November 3, 2022

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo 1.02%
3-mo -3.52%
6-mo N/A
1-year -32.05%
3-year -70.84%
5-year -55.93%
YTD -23.17%
2021 -58.46%
2020 -19.25%
2019 104.59%
2018 -2.40%
2017 2.13%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6863 seconds.